JP2022502055A5 - - Google Patents

Info

Publication number
JP2022502055A5
JP2022502055A5 JP2021517350A JP2021517350A JP2022502055A5 JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5 JP 2021517350 A JP2021517350 A JP 2021517350A JP 2021517350 A JP2021517350 A JP 2021517350A JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5
Authority
JP
Japan
Prior art keywords
sequence
guide
composition
seq
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502055A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053423 external-priority patent/WO2020069296A1/en
Publication of JP2022502055A publication Critical patent/JP2022502055A/ja
Publication of JP2022502055A5 publication Critical patent/JP2022502055A5/ja
Pending legal-status Critical Current

Links

JP2021517350A 2018-09-28 2019-09-27 乳酸デヒドロゲナーゼ(ldha)遺伝子編集のための組成物及び方法 Pending JP2022502055A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862738956P 2018-09-28 2018-09-28
US62/738,956 2018-09-28
US201962834334P 2019-04-15 2019-04-15
US62/834,334 2019-04-15
US201962841740P 2019-05-01 2019-05-01
US62/841,740 2019-05-01
PCT/US2019/053423 WO2020069296A1 (en) 2018-09-28 2019-09-27 Compositions and methods for lactate dehydrogenase (ldha) gene editing

Publications (2)

Publication Number Publication Date
JP2022502055A JP2022502055A (ja) 2022-01-11
JP2022502055A5 true JP2022502055A5 (cg-RX-API-DMAC7.html) 2022-09-30

Family

ID=68296656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517350A Pending JP2022502055A (ja) 2018-09-28 2019-09-27 乳酸デヒドロゲナーゼ(ldha)遺伝子編集のための組成物及び方法

Country Status (15)

Country Link
US (2) US20210222173A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856901A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022502055A (cg-RX-API-DMAC7.html)
KR (1) KR20210086621A (cg-RX-API-DMAC7.html)
CN (1) CN113056559A (cg-RX-API-DMAC7.html)
AU (1) AU2019347517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005718A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114425A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005231A2 (cg-RX-API-DMAC7.html)
IL (1) IL281529A (cg-RX-API-DMAC7.html)
MX (1) MX2021003457A (cg-RX-API-DMAC7.html)
PH (1) PH12021550686A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102660RA (cg-RX-API-DMAC7.html)
TW (1) TW202028460A (cg-RX-API-DMAC7.html)
WO (1) WO2020069296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004648A (ko) * 2019-03-28 2022-01-11 인텔리아 테라퓨틱스, 인크. Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
WO2022256655A2 (en) * 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2023122433A1 (en) * 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
IL314482A (en) 2022-02-02 2024-09-01 Regeneron Pharma Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法
WO2023212677A2 (en) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification of tissue-specific extragenic safe harbors for gene therapy approaches
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235726A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr interference therapeutics for c9orf72 repeat expansion disease
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
KR20250075694A (ko) 2022-09-28 2025-05-28 리제너론 파마슈티칼스 인코포레이티드 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
AU2024315073A1 (en) 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
EP4771049A1 (en) 2023-08-28 2026-07-08 Regeneron Pharmaceuticals, Inc. Cxcr4 antibody-resistant modified receptors
WO2025045247A1 (en) * 2023-08-31 2025-03-06 Geneditbio Limited Nucleic acids encoding crispr-associated proteins and uses thereof
EP4771154A2 (en) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025162435A1 (en) * 2024-02-02 2025-08-07 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of liver disease
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025265017A1 (en) 2024-06-20 2025-12-26 Regeneron Pharmaceuticals, Inc. Ass1 gene insertion for the treatment of citrullinemia type i

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
US10351854B2 (en) * 2014-10-10 2019-07-16 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
EP3452080A4 (en) * 2016-05-02 2019-10-09 The Regents of the University of California MAMMALIAN CELLS WITHOUT LACTATE DEHYDROGENASE ACTIVITY
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas

Similar Documents

Publication Publication Date Title
JP2021531804A5 (cg-RX-API-DMAC7.html)
JP2024178237A (ja) 修飾されたガイドrna
JP2022501040A5 (cg-RX-API-DMAC7.html)
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
US5744460A (en) Combination for treatment of proliferative diseases
JP2022527108A5 (cg-RX-API-DMAC7.html)
JP2022512703A5 (cg-RX-API-DMAC7.html)
JP2021526804A5 (cg-RX-API-DMAC7.html)
JP2018520685A (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP2023502038A5 (cg-RX-API-DMAC7.html)
JP2017516461A (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
CZ2003848A3 (cs) Způsob léčby poruch spojených s bcl-2 za použití antisense oligomerů bcl-2
JP2024516356A5 (cg-RX-API-DMAC7.html)
JP2022533358A5 (cg-RX-API-DMAC7.html)
IL277970B2 (en) Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
JP2022520986A5 (cg-RX-API-DMAC7.html)
JP2022518384A5 (cg-RX-API-DMAC7.html)
JP2019512543A (ja) β−カテニン関連疾患又は障害の治療のための組成物及び方法
JP2013504603A5 (cg-RX-API-DMAC7.html)
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
JP2002512792A (ja) インスリン様増殖因子iiアンチセンスオリゴヌクレオチド配列および細胞増殖を調節するためのその使用方法
JP5406024B2 (ja) Bcl−XL特異的siNAを用いる癌治療法
TW201038278A (en) Rnai molecule for thymidylate synthase and use thereof
JP2024543195A5 (cg-RX-API-DMAC7.html)
JP6437930B2 (ja) 悪性胸膜中皮腫を治療するためのマイクロrnaを基にしたアプローチ